Oral dosage forms comprising risedronate or a salt thereof a chelating agent and means for effecting delayed release of the risedronate (or salt) immediate release of the oral dosage form to the small intestine of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between the risedronate (or salt) and food or beverages which interaction results in the active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further disclosed is delivery of risedronate and the chelating agent to the small intestine substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies.

暂无附图